地舒单抗怎么用呢？

How to use it? In May 2019, Amgen China announced that denosumab was approved for marketing in my country. Due to the short time on the market, it has not been fully popularized in China. Let’s talk about how to use denosumab.

Desosumab is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival.

Desosumab is for the prevention of bone-related events in solid tumor bone metastases, but not for the prevention of bone-related events in patients with multiple myeloma: subcutaneous injection (upper arm, upper thigh, or abdomen) 120 mg once every 4 weeks, along with calcium or vitamin D infusion to prevent hypocalcemia.

Unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications: subcutaneous injection (upper arm, upper thigh or abdomen), 120 mg, once every 4 weeks. In the first month of treatment, 120 mg will be added on the 8th and 15th days respectively, and calcium or vitamin D will be infused to prevent hypocalcemia.

Hypercalcemia of malignant tumors: subcutaneous injection, 120 mg, once every 4 weeks. During the first month of treatment, add 120 mg on the 8th and 15th days respectively.

Hypocalcemia must be corrected before denosumab therapy can be initiated. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

Pregnant women and children should use it with caution. Desosumab is contraindicated in patients with allergies and hypocalcemia.

It is the first and currently the only drug in China for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.